<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pathogenesis of spondyloarthritis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pathogenesis of spondyloarthritis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pathogenesis of spondyloarthritis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Astrid van Tubergen, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joachim Sieper, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Philip Seo, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 17, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H8656926"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The term spondyloarthritis (SpA, formerly spondyloarthropathy) refers to a group of disorders that includes ankylosing spondylitis (AS), nonradiographic axial SpA (nr-axSpA), undifferentiated spondyloarthritis (USpA), reactive arthritis, and the arthritis and spondylitis that may accompany psoriasis and inflammatory bowel diseases (IBD). SpA can also be differentiated into axial and peripheral SpA, depending upon the predominant regions of involvement. Axial SpA includes both AS and nr-axSpA, based upon the presence or absence, respectively, of abnormalities of the sacroiliac joints on plain radiography.</p><p>This topic review will focus primarily on the pathogenesis of AS, regarding which the most is known. The pathogenesis of each of the other members of the SpA family, especially nr-axSpA, is probably closely related to that of AS [<a href="#rid1">1</a>]. The clinical manifestations, diagnosis, and treatment of AS are presented separately. (See  <a class="medical medical_review" href="/z/d/html/7785.html" rel="external">"Clinical manifestations of axial spondyloarthritis (ankylosing spondylitis and nonradiographic axial spondyloarthritis) in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7786.html" rel="external">"Diagnosis and differential diagnosis of axial spondyloarthritis (ankylosing spondylitis and nonradiographic axial spondyloarthritis) in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7790.html" rel="external">"Treatment of axial spondyloarthritis (ankylosing spondylitis and nonradiographic axial spondyloarthritis) in adults"</a>.)</p><p>The clinical aspects of the other types of SpA are also presented in detail elsewhere, as is SpA in children. (See  <a class="medical medical_review" href="/z/d/html/7785.html" rel="external">"Clinical manifestations of axial spondyloarthritis (ankylosing spondylitis and nonradiographic axial spondyloarthritis) in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7795.html" rel="external">"Clinical manifestations and diagnosis of peripheral spondyloarthritis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7794.html" rel="external">"Reactive arthritis"</a> and  <a class="medical medical_review" href="/z/d/html/7784.html" rel="external">"Clinical manifestations and diagnosis of psoriatic arthritis"</a> and  <a class="medical medical_review" href="/z/d/html/7787.html" rel="external">"Clinical manifestations and diagnosis of arthritis associated with inflammatory bowel disease and other gastrointestinal diseases"</a> and  <a class="medical medical_review" href="/z/d/html/6421.html" rel="external">"Spondyloarthritis in children"</a>.)</p><p class="headingAnchor" id="H503018377"><span class="h1">OVERVIEW OF PATHOGENESIS</span><span class="headingEndMark"> — </span>Several elements are important in the pathogenesis of spondyloarthritis (SpA), a group of diseases with diverse clinical manifestations, which involve several different structures  (<a class="graphic graphic_figure graphicRef113594" href="/z/d/graphic/113594.html" rel="external">figure 1</a>). These elements include interactions in the context of a particular genetic background between the gut microbiome, innate-like lymphoid cells, and mechanical stress at the anatomic structures that are disease targets. Those structures include, for axial SpA, the entheses along the axial skeleton and for peripheral SpA, the peripheral entheses and the peripheral joints. At the sites of pathology, the major mediators are tumor necrosis factor (TNF) alpha and interleukin (IL) 17. (See <a class="local">'Proinflammatory mediators validated by clinical observations'</a> below and <a class="local">'The gut mucosa, gut microbiome, and IL-17A'</a> below.)</p><p>The largest single genetic contribution is from the gene for human leukocyte antigen (HLA) B27, but the presence of HLA-B27 is not absolutely essential. Moreover, non-HLA genes and others are also involved. (See <a class="local">'Genetic factors'</a> below.)</p><p>A major challenge for investigators is that at the entheses, where ligaments are attached to the cartilage in the vertebrae, two different processes both occur that may seem paradoxical. One is inflammation, sometimes with destruction of bone (an osteoclastic process), while the other process is new bone formation leading to syndesmophytes (an osteoblastic process). At its worst, the new bone formation can convert the entire vertebral column into a rigid bamboo spine, the hallmark of severe ankylosing spondylitis (AS). A comprehensive hypothesis of SpA pathogenesis needs to address both the inflammatory osteoclastic and the osteoblastic processes. (See <a class="local">'Coexisting bone erosion and new bone formation'</a> below.)</p><p class="headingAnchor" id="H620882388"><span class="h1">PROINFLAMMATORY MEDIATORS VALIDATED BY CLINICAL OBSERVATIONS</span><span class="headingEndMark"> — </span>Among the variety of targeted therapies tested in spondyloarthritis (SpA) clinical trials, the only ones considered effective are aimed at one of three targets: Cyclooxygenase (COX), tumor necrosis factor (TNF) alpha, and interleukin (IL) 17A [<a href="#rid2">2-8</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cyclooxygenase</strong> – Inhibition of COX by nonsteroidal antiinflammatory drugs (NSAIDs) is very effective in controlling disease activity in some patients with SpA. This is probably because the COX enzymes are required for the generation of the proinflammatory compounds, the prostaglandins [<a href="#rid9">9</a>]. (See  <a class="medical medical_review" href="/z/d/html/7989.html" rel="external">"NSAIDs (including aspirin): Pharmacology and mechanism of action", section on 'Mechanisms of analgesia and antiinflammatory effects'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>TNF-alpha and IL-17</strong> – TNF itself is a pleiotropic cytokine released among other cells by macrophages, neutrophils, and lymphocytes. It is a strong inducer of a host of inflammatory mediators [<a href="#rid10">10</a>]. The targets of therapeutic TNF blockers are the innate immune response system, the prostaglandin system, the macrophages, and the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) pathway, as well as pathways downstream of NF-kB [<a href="#rid11">11</a>]. TNF blockers do not directly activate the T helper 1/T helper 17 (Th1/Th17) pathways.</p><p></p><p class="bulletIndent1">Blocking of IL-17 requires IL-17-specific blockers. There are six members in the IL-17 family, named IL-17A through IL-17F. Because IL-17A is the best characterized, the term IL-17, in general, refers to IL-17A. The engagement of IL-17A with its receptors leads to a cascade of pathways, which leads to activation of the transcription factors NFkB, AP-1, and C/EBP. These induce activation of genes encoding multiple inflammatory cytokines, chemokines, and metalloproteinases. Hence, IL-17A, like TNF-alpha, is also an orchestrator for a family of mediators [<a href="#rid12">12,13</a>]. IL-17A also acts in a positive feedback loop to enhance the production and effects of IL-17A. As a result of these interactions, IL-17A has a clinical effect that is as potent as that of TNF-alpha [<a href="#rid14">14-16</a>]. (See <a class="local">'Overview of pathogenesis'</a> above.)</p><p></p><p>Given that an ultimate goal of studying pathogenesis is to provide better therapy, the observations from clinical trials that these three classes of target-specific therapeutic agents are effective in at least some patients with SpA have been important contributions to the identification of critical elements in disease pathogenesis.</p><p class="headingAnchor" id="H425843135"><span class="h1">MAJOR ELEMENTS IN THE PATHOGENESIS OF SPONDYLOARTHRITIS</span><span class="headingEndMark"> — </span>The events that contribute to the pathogenesis of spondyloarthritis (SpA) are not a linearly linked series of cascades. It is a complex network of interactions involving the following:</p><p class="bulletIndent1"><span class="glyph">●</span>The axial skeleton and its entheses</p><p class="bulletIndent1"><span class="glyph">●</span>The peripheral entheses and joints</p><p class="bulletIndent1"><span class="glyph">●</span>Genetic influences</p><p class="bulletIndent1"><span class="glyph">●</span>The innate and perhaps also the adaptive immune systems</p><p class="bulletIndent1"><span class="glyph">●</span>The bowel</p><p></p><p>There are substantial variations among these elements, accounting for the enormous diversity of clinical presentations in SpA patients. As an example, these processes are thought to begin in the bowel, at least in patients with compromised bowel integrity. (See <a class="local">'The gut mucosa, gut microbiome, and IL-17A'</a> below.)</p><p class="headingAnchor" id="H1468315086"><span class="h1">THE GUT MUCOSA, GUT MICROBIOME, AND IL-17A</span></p><p class="headingAnchor" id="H1919747952"><span class="h2">Presence of mucosal lesions</span><span class="headingEndMark"> — </span>The gut microbiome has been incriminated as having a role in the pathogenesis of several types of inflammatory arthritis, including spondyloarthritis (SpA), in which defects in the gut mucosal barriers have been implicated in this process. Normally, the microbiome is separated from the host by a gut epithelial barrier and a gut vascular barrier [<a href="#rid17">17</a>]. However, when the integrity of the barriers is compromised, the microbes become capable of initiating a systemic immune response [<a href="#rid18">18</a>]. Lesions in the gut mucosa in patients with SpA were first demonstrated in the 1980s [<a href="#rid19">19</a>]. Additional evidence supporting a role for these issues in pathogenesis includes [<a href="#rid20">20,21</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The demonstration by ileocolonoscopy of the presence of subclinical acute or chronic intestinal inflammation in about two-thirds of patients with SpA, with functional breaches in the gut epithelium in SpA</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The correlation between chronic gut inflammation and magnetic resonance imaging (MRI)-demonstrable SpA disease activity</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The sharing of genes between ankylosing spondylitis (AS) and Crohn disease</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The presence of AS in 4 to 10 percent of patients with ulcerative colitis and Crohn disease</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Findings of sacroiliitis on plain radiographs in a significant proportion of patients with Crohn disease, many of whom do not have symptoms of inflammatory back pain</p><p></p><p class="headingAnchor" id="H2699185479"><span class="h2">SpA-specific gut microbiome and damage of intestinal mucosal barriers</span><span class="headingEndMark"> — </span>The composition of the gut microbiome, which is influenced by genetic and other factors, differs in patients with SpA from healthy individuals. Evidence in both humans and more so in animal models supports the view that the gut microbiome plays a vanguard role in the cascade of events leading to inflammation in many patients with SpA.</p><p>The strongest evidence that the gut microbiome is necessary for development of SpA comes from animal models [<a href="#rid22">22</a>]. In these models, rats and mice develop SpA-like clinical and pathologic features when housed in their usual laboratory environment; however, they fail to develop such features when raised in a germ-free environment, although the SpA-like features do appear when the animals are brought out of the germ-free environment.</p><p>Data in humans also argue for a role of the gut microbiome in disease pathogenesis. The enormous diversity in the trillions of commensal microbial cells in the human gut is affected by multiple factors, including geography, ethnicity, major histocompatability complex (MHC) genes, therapy, age, sex, and diet. A description, or "census," of the microbiota in each individual can allow for the characterization of that individual's microbiome by sequencing and analytic techniques [<a href="#rid23">23,24</a>]. Using this approach, a core microbiome set can be demonstrated, which is unique for each person at a given point in time and has the capacity to distinguish between different individuals [<a href="#rid25">25</a>].</p><p>A large number of studies have been reported comparing the gut microbiome between SpA and healthy subjects, consistently demonstrating differences in the microbiome between SpA and healthy subjects. However, findings concerning the particular SpA-specific microbial species vary between studies. What appears to be more consistent is that the SpA microbiome is more enriched in species that are mucolytic and potentially able to degrade the gut barrier. Breakdowns were demonstrated by immunohistologic findings of the downregulation of junctional proteins and evidence of increased serum levels of bacterial lipopolysaccharides [<a href="#rid26">26-31</a>].</p><p class="headingAnchor" id="H4144062571"><span class="h2">IL-17 and gut microbial invasion</span><span class="headingEndMark"> — </span>The loss of architectural and functional integrity in the intestinal epithelium allows for passage of microbiota or their metabolites into the submucosa and the systemic circulation (see <a class="local">'SpA-specific gut microbiome and damage of intestinal mucosal barriers'</a> above). The first line of cytokine defense is IL-17. Acting in synergy with IL-22, it guards the integrity of the gut epithelium against microbes by inducing the generation of anti-microbial peptides. These effects are probably why there is a higher incidence of inflammatory bowel disease (IBD) flares in the anti-IL-17-treated patients in clinical trials of anti-IL-17 in psoriasis and AS, compared with placebo-treated patients [<a href="#rid32">32</a>]. There are multiple factors that can drive a variety of cell types to generate IL-17 [<a href="#rid12">12,33</a>].</p><p>Although the IL-17 cells activating IL-23 were at one time considered the most likely orchestrating disease-causing candidate in SpA, multiple randomized trials have failed to demonstrate a significant clinical benefit of two different anti-IL-23 antibodies in AS. This is despite the efficacy of both antibodies for psoriasis [<a href="#rid34">34,35</a>]. Hence, the IL-17-producing cells in AS are probably predominantly IL-23-independent [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H1528141582"><span class="h2">Potential roles of several types of IL-17-positive cells</span><span class="headingEndMark"> — </span>Besides the granulocytes and macrophages, several other types of cells in the intestine are capable of producing IL-17. These include the type 3 innate-like lymphoid cells (ILC3), mucosal-associated T cells (MAIT), gamma-delta T cells, innate-like invariant natural killer T cells (iNKT), and mast cells [<a href="#rid16">16,37</a>]. The ILC and the innate-like T cells recognize microbial products without requiring extensive rearrangement of their T-cell receptors [<a href="#rid29">29,38</a>]. Because of this, they can rapidly produce a large quantity of cytokines [<a href="#rid36">36,39</a>]<em>.</em></p><p>ILC3 is an example of how the innate immune cells can travel from the gut to the entheses and joints  (<a class="graphic graphic_figure graphicRef113594" href="/z/d/graphic/113594.html" rel="external">figure 1</a>) [<a href="#rid40">40-42</a>]. Upon becoming activated in the gut, these ILC3 express the alpha-4/beta-7 integrin, which can function as a homing receptor. The ligand for this integrin is mucosal vascular addressin cell adhesion molecule 1 (MADCAM1), which, in patients with AS, is strongly expressed in the high endothelial venules (HEV) of the gut and bone marrow [<a href="#rid41">41</a>]. Although not directly demonstrated, these gut-derived ILC3 in patients with AS are postulated to migrate into the systemic circulation and to home via this integrin-ligand interaction towards the bone marrow, the peripheral joints, and the entheses [<a href="#rid2">2,43,44</a>].</p><p>Alternately, such IL-17-positive cells might originate in areas other than the gut such as the entheses and the bone marrow.</p><p class="headingAnchor" id="H1359005995"><span class="h2">Entheses and the role of mechanical stress</span><span class="headingEndMark"> — </span>The major targets of the disease process in patients with SpA are the entheses, where tendons and ligaments are attached to bone [<a href="#rid45">45</a>]. Because of the mechanical load, entheses are highly susceptible to micro-injury. The attachment of the Achilles tendon to the calcaneus, for example, is subjected to mechanical stress of 3 to 10 times the body weight during activities. Such micro-injuries can activate resident immune cells that include the ILC, gamma delta T cells, natural killer cells, and conventional T cells. Together with the neutrophils, they also release chemoattractants for circulatory proinflammatory cells. All these cells orchestrate a TNF- and IL-17-dependent inflammatory reaction even in subjects with no arthritis. It is postulated that SpA is caused by a faulty fine-tuning of this local reactivity [<a href="#rid46">46-48</a>]. The proportion of peripheral blood T cells carrying surface markers of regulatory T cells (Treg) is lower in AS patients [<a href="#rid49">49</a>]. One possible contributory factor is that their proliferation is inhibited by microribonucleic acids (microRNAs) carried in exosomes [<a href="#rid50">50</a>].</p><p class="headingAnchor" id="H204843856"><span class="h1">GENETIC FACTORS</span><span class="headingEndMark"> — </span>Genetic factors have overwhelming importance in susceptibility to ankylosing spondylitis (AS). First-, second-, and third-degree relatives of patients with AS have markedly increased risks of developing the disease (relative risks of 94, 25, and 4, respectively) [<a href="#rid4">4</a>]. The mode of inheritance is polygenic with multiplicative interaction among loci [<a href="#rid5">5,6</a>]. The association with the human leukocyte antigen (HLA) B27 gene was recognized in 1973 and has the strongest association with the disease  (<a class="graphic graphic_table graphicRef85593" href="/z/d/graphic/85593.html" rel="external">table 1</a>) [<a href="#rid7">7,51</a>]. The overall contribution to AS heritability by HLA-B27 is estimated at approximately 20 to 30 percent [<a href="#rid52">52</a>]. The contribution of the major histocompatability complex (MHC) region is 40 to 50 percent [<a href="#rid36">36</a>]. (See <a class="local">'Role of HLA-B27'</a> below.)</p><p class="headingAnchor" id="H261498424"><span class="h2">Role of HLA-B27</span><span class="headingEndMark"> — </span>Because HLA-B27 is present in approximately 80 to 95 percent of patients with AS in most ethnic groups, compared, for example, with 6 percent of the general population in the United States, it is assumed to play a major role in the pathogenesis of AS. At least 160 subtypes of HLA-B27 have been characterized; differences between these subtypes affect whether they are associated with spondyloarthritis (SpA), including AS [<a href="#rid51">51,53-55</a>]. The most frequent subtypes are HLA-B2705 and HLA-B2704 [<a href="#rid53">53,56,57</a>]. Only two subtypes, HLA-B2706 and HLA-B2709, are considered not to be associated with SpA [<a href="#rid4">4,58,59</a>].</p><p>At this point, it is still unclear what role HLA-B27 plays in the pathogenesis of SpA [<a href="#rid60">60</a>]. Besides its role in cell-mediated immunity, studies in healthy HLA-B27 positive individuals have shown that there is an association of the HLA-B27 genotype with the overall gut microbial composition, which is distinct from the composition of the gut microbiome that is observed in subjects without HLA-B27 [<a href="#rid61">61,62</a>]. These findings may relate to the proposed role of the gut microbiome in the pathogenesis of SpA, and will be a focus of further research.</p><p>Most research on the role of HLA-B27 in the pathogenesis of SpA has historically focused on how different structures of HLA-B27 mediate inflammatory processes. Although no fully satisfactory explanations have been established, it is clear that the entire set of intracellular processes of formation of the HLA-B27 molecule need to be considered  (<a class="graphic graphic_figure graphicRef116008" href="/z/d/graphic/116008.html" rel="external">figure 2</a>).</p><p class="headingAnchor" id="H8656962"><span class="h3">Classical (canonical) structure of HLA-B27</span><span class="headingEndMark"> — </span>Several features distinguish HLA-B27 from most other HLA class I molecules; these features may be relevant to disease susceptibility according to some hypotheses. The classical (canonical) structure is one shared with other HLA class I molecules [<a href="#rid63">63-66</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The HLA class I molecule is composed of a 45 kD polymorphic heavy chain, noncovalently complexed with a 12 kD monomorphic unit, beta-2-microglobulin.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The heavy chain is composed of three domains. The first two domains (alpha-1 and alpha-2) together form two antiparallel helices resting on a platform of an eight-stranded pleated sheet, which itself rests on two barrel-shaped structures derived from the complex of the third domain (alpha-3) and the beta-2-microglobulin  (<a class="graphic graphic_figure graphicRef71117" href="/z/d/graphic/71117.html" rel="external">figure 3</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An antigenic peptide that is usually 8 to 11 amino acids in length rests inside the platform. These peptides are derived from endogenous proteins and from proteins of viruses and bacteria that have invaded the cells  (<a class="graphic graphic_figure graphicRef68628" href="/z/d/graphic/68628.html" rel="external">figure 4</a>).</p><p></p><p>The features that distinguish HLA-B27 from most other HLA class I molecules include:</p><p class="bulletIndent1"><span class="glyph">●</span>Most antigenic peptides associated with HLA-B27 have arginine as the second residue [<a href="#rid63">63-65</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The presence of an unpaired cysteine at residue 67 (Cys67) – This unique feature allows for the formation of homodimers and oligomers of free heavy chains. (See <a class="local">'HLA-B27 misfolding and autophagy'</a> below.)</p><p></p><p>Since the physiologic function of <em>HLA-B</em> alleles is for CD8+ T lymphocyte to present peptides to the corresponding T-cell receptors on target cells, the favorite hypothesis for SpA is the "arthritogenic peptide hypothesis." It postulates that there are certain microbial peptides that are very similar to self-peptides from the point of view of the T-cell receptors of certain HLA-B27-specific CD8+ T lymphocytes (cytotoxic T lymphocytes). The reactivity of these T lymphocytes with these HLA-B27-peptide complexes would then lead to autoreactivity and autoimmune disease [<a href="#rid67">67-69</a>]. There is indeed an enrichment of such bacterial peptides in the stool of patients with AS [<a href="#rid70">70</a>]. Most importantly, this hypothesis is supported by multiple studies of T cell profiling to identify both the responsible T-cell receptors as well as the cross-reactive self and microbial peptides [<a href="#rid71">71,72</a>]. This approach can lead to refinement in diagnosis as well as targeted therapies.</p><p class="headingAnchor" id="H3044546051"><span class="h3">HLA-B27 as free heavy chains</span><span class="headingEndMark"> — </span>HLA-B27 can also exist as a dimer of two heavy chains without the beta-2-microglobulin [<a href="#rid73">73-75</a>]; these proteins may contribute to the pathogenesis of SpA. These dimers are present in the gut and synovium of SpA patients. When present on antigen-presenting cells, they can stimulate interleukin (IL) 23 receptor positive T cells to produce IL-17 [<a href="#rid76">76</a>]<em>.</em></p><p class="headingAnchor" id="H808524978"><span class="h3">HLA-B27 misfolding and autophagy</span><span class="headingEndMark"> — </span>HLA-B27 folds more slowly than other HLA molecules into the canonical class I structure inside the endoplasmic reticulum, where it may accumulate and influence pathways promoting the production of immune mediators important in the development of SpA. The misfolding hypothesis explaining the HLA-B27 association with SpA is based upon a feature of molecular biogenesis peculiar to HLA-B27, by which HLA-B27 could begin to induce SpA before it reaches the surface of the cell due to protein misfolding [<a href="#rid77">77,78</a>]. The HLA-B27 misfolding hypothesis can be summarized as follows  (<a class="graphic graphic_figure graphicRef68574" href="/z/d/graphic/68574.html" rel="external">figure 5</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Mature HLA-B27 has a quaternary structure with three different components. It is assembled and folded from a linear structure in the endoplasmic reticulum, a cellular compartment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For several reasons, including the cysteine residue at position 67, the folding process of HLA-B27 is slower than that for other HLA alleles.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Improperly folded HLA-B27 proteins (ie, those not yet in the canonical mature class I conformation) accumulate in the endoplasmic reticulum.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>This can lead to a misfolding process, which activates autophagy and activation of the IL-23/IL-17 pathway. Alternately, misfolding can lead to another process termed the endoplasmic reticulum unfolded protein response (ERUPR), which can also activate the IL-23/IL-17 pathway  (<a class="graphic graphic_figure graphicRef55882" href="/z/d/graphic/55882.html" rel="external">figure 6</a>). (See <a class="local">'Coexisting bone erosion and new bone formation'</a> below.)</p><p></p><p class="bulletIndent1">The likelihood is that misfolding of HLA-B27 leads only to autophagy, and it is this autophagy which activates the IL-23/IL-17 pathway [<a href="#rid36">36</a>]. One type of cells that undergo autophagy in AS are the Paneth cells in the intestinal epithelial lining [<a href="#rid43">43,79</a>].</p><p></p><p class="headingAnchor" id="H3002073334"><span class="h2">Non-HLA genes</span><span class="headingEndMark"> — </span>The search for non-HLA-B27 genes that may be important in SpA pathogenesis has focused almost exclusively on patients with AS and has suggested that non-MHC genes are also important in disease susceptibility. Since 2010, several large genome-wide association studies (GWAS) have been carried out in several populations of European [<a href="#rid80">80-82</a>] and Han Chinese descent [<a href="#rid83">83</a>]. These studies have identified a total of at least 114 genetic variants. The MHC, especially HLA-B27, is a major contributory factor. Approximately 7 percent of the heritable risk is from non-MHC variants  (<a class="graphic graphic_table graphicRef85593" href="/z/d/graphic/85593.html" rel="external">table 1</a>) [<a href="#rid52">52,84-89</a>]. The apparent need for an HLA-B27-positive individual to also carry some of these non-MHC genes in order to develop AS may explain, at least in part, why only 1 to 5 percent of HLA-B27-positive individuals develop AS.</p><p>Even though the total contribution of all these non-MHC genes to AS heritability is relatively small, these associations provide clues about the pathogenesis of AS. In addition, their significance can be amplified by gene-gene interaction [<a href="#rid90">90</a>]. These non-MHC AS-causing genes can be grouped into several functional categories:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>ERAP1 and ERAP2</strong> – The two endoplasmic reticulum aminopeptidases that encode genes related to AS are termed ERAP1 and ERAP2; each of the genes has variants that may increase the risk of AS and variants that are protective. These two enzymes are responsible for the generation as well as trimming and destruction of peptides in the endoplasmic reticulum to achieve the correct length for loading into HLA class I molecules, such as HLA-B27, for antigen presentation [<a href="#rid91">91</a>]. The actual significance of ERAP1 and ERAP2 in SpA is still not entirely clear [<a href="#rid76">76,92</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tumor necrosis factor receptor gene family</strong> – The presence of an additional group of genes, including those for the lymphotoxin beta receptor (<em>LTBR</em>) and tumor necrosis factor receptor 1 (<em>TNFRSF1A</em>), provides additional support for the role of tumor necrosis factor (TNF) alpha in disease activity [<a href="#rid52">52</a>]. (See <a class="local">'Proinflammatory mediators validated by clinical observations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IL-23/IL-17 axis</strong> – GWAS have identified a number of genes that are associated with the IL-23/IL-17 axis [<a href="#rid84">84</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>T lymphocyte activation and differentiation</strong> – The association of AS with genes modulating activation and differentiation of either CD4+ or CD8+ T lymphocytes is consistent with potential involvement of these cells with disease pathways.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genes shared with inflammatory and immune-mediated bowel disease</strong> – The sharing of 65 genes with Crohn disease, ulcerative colitis, and celiac disease may explain the overlap of AS with inflammatory bowel diseases (IBD) and perhaps the presence of subclinical bowel disease in AS itself [<a href="#rid84">84</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>A gene associated with radiographic progress in AS</strong> – The genes listed above are associated with susceptibility of disease. In AS, spinal damage is the most disabling factor. Using GWAS in 444 AS patients, 1 study identified a gene known as ryanodine receptor 3 (<em>RYR3</em>), which was associated with severity of radiographic spinal damages [<a href="#rid93">93</a>]. <em>RYR3</em> encodes a channel release protein that regulates intracellular calcium homeostasis. It is expressed in musculoskeletal tissues.</p><p></p><p>How these various genes are activated to express their respective proteins and how their expression is modulated in flares and relapses of AS remain to be clarified.</p><p>More advanced nucleotide-based technologies might be able to answer these questions. These include whole genome sequencing, studies of microribonucleic acid (microRNA), methylation, and histone acetylation [<a href="#rid94">94</a>].</p><p class="headingAnchor" id="H114573112"><span class="h1">COEXISTING BONE EROSION AND NEW BONE FORMATION</span><span class="headingEndMark"> — </span>The mechanisms by which bone inflammation and erosions can occur in patients with spondyloarthritis (SpA) along with new bone formation have not been fully elucidated. These findings may appear paradoxical and there is controversy regarding the interpretation of the available data. The findings in SpA are in contrast with those in rheumatoid arthritis (RA), where only bone erosion is observed.</p><p>One clue is provided by longitudinal studies of the spine in the same patients using MRI and radiography. Using two different sequences, MRI can visualize both inflammation and repair processes, identified respectively as bone marrow edema and fat metaplasia. New bone formation (for example, syndesmophytes) is best visualized by plain radiography. These studies suggest that the initial change is inflammation in which cytokines such as tumor necrosis factor (TNF) and IL-17 directly or indirectly activate osteoclast precursor cells. This is then followed to a certain extent by a reparative process at the vertebral corners and other sites of the axial skeleton, and finally by new bone formation (such as syndesmophytes)  (<a class="graphic graphic_figure graphicRef116045" href="/z/d/graphic/116045.html" rel="external">figure 7</a>) [<a href="#rid95">95</a>]. Cross-sectional studies of the histology indicate that new bone formation is more likely to take place in areas where there has been fat metaplasia and that new bone formation appears after the inflammation has subsided [<a href="#rid96">96</a>]. Osteoblast differentiation involves use of the bone morphogenic proteins and the Wnt pathway [<a href="#rid45">45</a>]. Several biomarkers have been identified that seem to mediate or inhibit the process of new bone formation [<a href="#rid97">97</a>].</p><p>New bone formation does not occur in the vertebral body, where the inflammation has destroyed the microarchitecture; rather, syndesmophyte are formed at the periosteum-cartilage junction. The most important players are the stromal cells: the bone marrow mesenchymal cells (BM-MSC) and the fibroblast-like synovial cells (FLS). Normally, the BM-MSC reside in the bone marrow, but they are capable of migrating through pores into the entheses. There, mesenchymal cells are driven into osteogenesis by interleukin (IL) 22, IL-17, and TNF. These mesenchymal cells also secrete a chemokine to augment the reactivity [<a href="#rid16">16,48,98</a>]. The FLS on the other hand can develop into osteoblasts even independent of an inflammatory environment [<a href="#rid37">37</a>].</p><p>Another set of observations found that in the mesenchymal cells of the spinal entheses of ankylosing spondylitis (AS) patients, human leukocyte antigen (HLA) B27 unfolding response activates a pathway leading to generation of tissue-nonspecific alkaline phosphatase (TNAP). Clinical significance is suggested by the finding that serum levels of bone-specific TNAP correlate with scoring vertebral changes in AS patients [<a href="#rid99">99</a>]. Yet another clue is that serum migratory inhibitory factor (MIF) is raised in patients with AS and can predict radiographic progression [<a href="#rid100">100,101</a>].</p><p class="headingAnchor" id="H8657054"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/577.html" rel="external">"Patient education: Axial spondyloarthritis, including ankylosing spondylitis (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H8657060"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>The major areas of involvement in ankylosing spondylitis (AS) and the other forms of spondyloarthritis (SpA) are at the articulations of the axial skeleton, at the interface between ligaments/tendons/bone/cartilage (entheses). (See <a class="local">'Overview of pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mediators that are current targets of therapy are the cyclooxygenases (COX), tumor necrosis factor (TNF) alpha, and interleukin (IL) 17, emphasizing the significance of these enzymes and cytokines to processes important in the pathogenesis of SpA. (See <a class="local">'Proinflammatory mediators validated by clinical observations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with microscopic bowel lesions, the disease processes probably start in the gut, where several types of rapidly responding cells such as the innate lymphoid cells (ILCs) that produce IL-17 (a proinflammatory cytokine) and IL-22 are activated by SpA-specific gut microbiota  (<a class="graphic graphic_figure graphicRef113594" href="/z/d/graphic/113594.html" rel="external">figure 1</a>). (See <a class="local">'The gut mucosa, gut microbiome, and IL-17A'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Innate-like immune cells activated in the gut migrate to the entheses and the joints, causing an inflammatory process in which TNF-alpha also participates. IL-17 causes a bone-erosive process. (See <a class="local">'IL-17 and gut microbial invasion'</a> above and <a class="local">'Coexisting bone erosion and new bone formation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The entheses themselves also contain several types of these cells, which can be activated via mechanical stress to generate IL-17. (See <a class="local">'Entheses and the role of mechanical stress'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The pathogenic events in SpA take place in a complex genetic background. The major gene is human leukocyte antigen (HLA) B27, which probably participates in several of the key pathogenic processes. Additionally, a large number of non-HLA genes have also been identified as having associations with AS. They interact and reinforce several of the disease-causing pathways. (See <a class="local">'Genetic factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Initial changes in bone result from inflammation, followed by a reparative process via the mesenchymal cells of the entheses via the effect of IL-22 and IL-17 on mesenchymal cells. The ultimate consequence is new bone formation, such as the formation of syndesmophytes  (<a class="graphic graphic_figure graphicRef116045" href="/z/d/graphic/116045.html" rel="external">figure 7</a>). (See <a class="local">'Coexisting bone erosion and new bone formation'</a> above.)</p><p></p><p class="headingAnchor" id="H279690304"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges David Yu, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Baeten D, Breban M, Lories R, et al. Are spondylarthritides related but distinct conditions or a single disease with a heterogeneous phenotype? Arthritis Rheum 2013; 65:12.</a></li><li><a class="nounderline abstract_t">Kim CH, Hashimoto-Hill S, Kim M. Migration and Tissue Tropism of Innate Lymphoid Cells. Trends Immunol 2016; 37:68.</a></li><li><a class="nounderline abstract_t">Sherlock JP, Buckley CD, Cua DJ. The critical role of interleukin-23 in spondyloarthropathy. Mol Immunol 2014; 57:38.</a></li><li><a class="nounderline abstract_t">Taurog JD. The mystery of HLA-B27: if it isn't one thing, it's another. Arthritis Rheum 2007; 56:2478.</a></li><li><a class="nounderline abstract_t">Brown MA, Kennedy LG, MacGregor AJ, et al. Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment. Arthritis Rheum 1997; 40:1823.</a></li><li><a class="nounderline abstract_t">Brown MA, Laval SH, Brophy S, Calin A. Recurrence risk modelling of the genetic susceptibility to ankylosing spondylitis. Ann Rheum Dis 2000; 59:883.</a></li><li><a class="nounderline abstract_t">Brewerton DA, Hart FD, Nicholls A, et al. Ankylosing spondylitis and HL-A 27. Lancet 1973; 1:904.</a></li><li><a class="nounderline abstract_t">Tahir H. Therapies in ankylosing spondylitis-from clinical trials to clinical practice. Rheumatology (Oxford) 2018; 57:vi23.</a></li><li><a class="nounderline abstract_t">Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol 2011; 31:986.</a></li><li><a class="nounderline abstract_t">Kalliolias GD, Ivashkiv LB. TNF biology, pathogenic mechanisms and emerging therapeutic strategies. Nat Rev Rheumatol 2016; 12:49.</a></li><li><a class="nounderline abstract_t">Menegatti S, Guillemot V, Latis E, et al. Immune response profiling of patients with spondyloarthritis reveals signalling networks mediating TNF-blocker function in vivo. Ann Rheum Dis 2021; 80:475.</a></li><li><a class="nounderline abstract_t">Raychaudhuri SP, Raychaudhuri SK. Mechanistic rationales for targeting interleukin-17A in spondyloarthritis. Arthritis Res Ther 2017; 19:51.</a></li><li><a class="nounderline abstract_t">McGonagle DG, McInnes IB, Kirkham BW, et al. The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies. Ann Rheum Dis 2019; 78:1167.</a></li><li><a class="nounderline abstract_t">Veldhoen M. Interleukin 17 is a chief orchestrator of immunity. Nat Immunol 2017; 18:612.</a></li><li><a class="nounderline abstract_t">Poddubnyy D, Sieper J. What is the best treatment target in axial spondyloarthritis: tumour necrosis factor α, interleukin 17, or both? Rheumatology (Oxford) 2018; 57:1145.</a></li><li><a class="nounderline abstract_t">Groen SS, Sinkeviciute D, Bay-Jensen AC, et al. Exploring IL-17 in spondyloarthritis for development of novel treatments and biomarkers. Autoimmun Rev 2021; 20:102760.</a></li><li><a class="nounderline abstract_t">Spadoni I, Zagato E, Bertocchi A, et al. A gut-vascular barrier controls the systemic dissemination of bacteria. Science 2015; 350:830.</a></li><li><a class="nounderline abstract_t">Jethwa H, Abraham S. The evidence for microbiome manipulation in inflammatory arthritis. Rheumatology (Oxford) 2017; 56:1452.</a></li><li><a class="nounderline abstract_t">Cypers H, Van Praet L, Varkas G, Elewaut D. Relevance of the gut/joint axis for the management of spondyloarthritis in daily clinical practice. Curr Opin Rheumatol 2014; 26:371.</a></li><li><a class="nounderline abstract_t">Van Praet L, Van den Bosch F, Mielants H, Elewaut D. Mucosal inflammation in spondylarthritides: past, present, and future. Curr Rheumatol Rep 2011; 13:409.</a></li><li><a class="nounderline abstract_t">Danoy P, Pryce K, Hadler J, et al. Association of variants at 1q32 and STAT3 with ankylosing spondylitis suggests genetic overlap with Crohn's disease. PLoS Genet 2010; 6:e1001195.</a></li><li><a class="nounderline abstract_t">Vieira-Sousa E, van Duivenvoorde LM, Fonseca JE, et al. Review: animal models as a tool to dissect pivotal pathways driving spondyloarthritis. Arthritis Rheumatol 2015; 67:2813.</a></li><li><a class="nounderline abstract_t">Ursell LK, Metcalf JL, Parfrey LW, Knight R. Defining the human microbiome. Nutr Rev 2012; 70 Suppl 1:S38.</a></li><li><a class="nounderline abstract_t">Carding S, Verbeke K, Vipond DT, et al. Dysbiosis of the gut microbiota in disease. Microb Ecol Health Dis 2015; 26:26191.</a></li><li><a class="nounderline abstract_t">Franzosa EA, Huang K, Meadow JF, et al. Identifying personal microbiomes using metagenomic codes. Proc Natl Acad Sci U S A 2015; 112:E2930.</a></li><li><a class="nounderline abstract_t">Tito RY, Cypers H, Joossens M, et al. Brief Report: Dialister as a Microbial Marker of Disease Activity in Spondyloarthritis. Arthritis Rheumatol 2017; 69:114.</a></li><li><a class="nounderline abstract_t">Costello ME, Ciccia F, Willner D, et al. Brief Report: Intestinal Dysbiosis in Ankylosing Spondylitis. Arthritis Rheumatol 2015; 67:686.</a></li><li><a class="nounderline abstract_t">Breban M, Tap J, Leboime A, et al. Faecal microbiota study reveals specific dysbiosis in spondyloarthritis. Ann Rheum Dis 2017; 76:1614.</a></li><li><a class="nounderline abstract_t">Dumas E, Venken K, Rosenbaum JT, Elewaut D. Intestinal Microbiota, HLA-B27, and Spondyloarthritis: Dangerous Liaisons. Rheum Dis Clin North Am 2020; 46:213.</a></li><li><a class="nounderline abstract_t">Breban M, Beaufrère M, Glatigny S. The microbiome in spondyloarthritis. Best Pract Res Clin Rheumatol 2019; 33:101495.</a></li><li><a class="nounderline abstract_t">Ciccia F, Guggino G, Rizzo A, et al. Dysbiosis and zonulin upregulation alter gut epithelial and vascular barriers in patients with ankylosing spondylitis. Ann Rheum Dis 2017; 76:1123.</a></li><li><a class="nounderline abstract_t">Hohenberger M, Cardwell LA, Oussedik E, Feldman SR. Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease. J Dermatolog Treat 2018; 29:13.</a></li><li><a class="nounderline abstract_t">Valeri M, Raffatellu M. Cytokines IL-17 and IL-22 in the host response to infection. Pathog Dis 2016; 74.</a></li><li><a class="nounderline abstract_t">Deodhar A, Gensler LS, Sieper J, et al. Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis. Arthritis Rheumatol 2019; 71:258.</a></li><li><a class="nounderline abstract_t">Baeten D, Østergaard M, Wei JC, et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann Rheum Dis 2018; 77:1295.</a></li><li><a class="nounderline abstract_t">Mauro D, Thomas R, Guggino G, et al. Ankylosing spondylitis: an autoimmune or autoinflammatory disease? Nat Rev Rheumatol 2021; 17:387.</a></li><li><a class="nounderline abstract_t">Mauro D, Simone D, Bucci L, Ciccia F. Novel immune cell phenotypes in spondyloarthritis pathogenesis. Semin Immunopathol 2021; 43:265.</a></li><li><a class="nounderline abstract_t">Lanier LL. Shades of grey--the blurring view of innate and adaptive immunity. Nat Rev Immunol 2013; 13:73.</a></li><li><a class="nounderline abstract_t">Mortier C, Govindarajan S, Venken K, Elewaut D. It Takes "Guts" to Cause Joint Inflammation: Role of Innate-Like T Cells. Front Immunol 2018; 9:1489.</a></li><li><a class="nounderline abstract_t">Sonnenberg GF, Artis D. Innate lymphoid cell interactions with microbiota: implications for intestinal health and disease. Immunity 2012; 37:601.</a></li><li><a class="nounderline abstract_t">Ciccia F, Guggino G, Rizzo A, et al. Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis. Ann Rheum Dis 2015; 74:1739.</a></li><li><a class="nounderline abstract_t">Cuthbert RJ, Fragkakis EM, Dunsmuir R, et al. Brief Report: Group 3 Innate Lymphoid Cells in Human Enthesis. Arthritis Rheumatol 2017; 69:1816.</a></li><li><a class="nounderline abstract_t">Ciccia F, Rizzo A, Triolo G. Subclinical gut inflammation in ankylosing spondylitis. Curr Opin Rheumatol 2016; 28:89.</a></li><li><a class="nounderline abstract_t">Kempster SL, Kaser A. α4β7 integrin: beyond T cell trafficking. Gut 2014; 63:1377.</a></li><li><a class="nounderline abstract_t">Schett G, Lories RJ, D'Agostino MA, et al. Enthesitis: from pathophysiology to treatment. Nat Rev Rheumatol 2017; 13:731.</a></li><li><a class="nounderline abstract_t">Cambré I, Gaublomme D, Burssens A, et al. Mechanical strain determines the site-specific localization of inflammation and tissue damage in arthritis. Nat Commun 2018; 9:4613.</a></li><li><a class="nounderline abstract_t">Gracey E, Burssens A, Cambré I, et al. Tendon and ligament mechanical loading in the pathogenesis of inflammatory arthritis. Nat Rev Rheumatol 2020; 16:193.</a></li><li><a class="nounderline abstract_t">Russell T, Bridgewood C, Rowe H, et al. Cytokine "fine tuning" of enthesis tissue homeostasis as a pointer to spondyloarthritis pathogenesis with a focus on relevant TNF and IL-17 targeted therapies. Semin Immunopathol 2021; 43:193.</a></li><li><a class="nounderline abstract_t">Lai NL, Zhang SX, Wang J, et al. The Proportion of Regulatory T Cells in Patients with Ankylosing Spondylitis: A Meta-Analysis. J Immunol Res 2019; 2019:1058738.</a></li><li><a class="nounderline abstract_t">Tavasolian F, Lively S, Pastrello C, et al. Proteomic and genomic profiling of plasma exosomes from patients with ankylosing spondylitis. Ann Rheum Dis 2023; 82:1429.</a></li><li><a class="nounderline abstract_t">Schlosstein L, Terasaki PI, Bluestone R, Pearson CM. High association of an HL-A antigen, W27, with ankylosing spondylitis. N Engl J Med 1973; 288:704.</a></li><li><a class="nounderline abstract_t">Reveille JD. Genetics of spondyloarthritis--beyond the MHC. Nat Rev Rheumatol 2012; 8:296.</a></li><li><a class="nounderline abstract_t">Uchanska-Ziegler B, Ziegler A, Schmieder P. Structural and dynamic features of HLA-B27 subtypes. Curr Opin Rheumatol 2013; 25:411.</a></li><li><a class="nounderline abstract_t">Reveille JD. Recent studies on the genetic basis of ankylosing spondylitis. Curr Rheumatol Rep 2009; 11:340.</a></li><li class="breakAll">International ImMunoGeneTics project IMGT/HLA Database. http://www.ebi.ac.uk/ipd/imgt/hla/ (Accessed on February 12, 2014).</li><li><a class="nounderline abstract_t">Sorrentino R, Böckmann RA, Fiorillo MT. HLA-B27 and antigen presentation: at the crossroads between immune defense and autoimmunity. Mol Immunol 2014; 57:22.</a></li><li><a class="nounderline abstract_t">Wucherpfennig KW. Presentation of a self-peptide in two distinct conformations by a disease-associated HLA-B27 subtype. J Exp Med 2004; 199:151.</a></li><li><a class="nounderline abstract_t">D'Amato M, Fiorillo MT, Carcassi C, et al. Relevance of residue 116 of HLA-B27 in determining susceptibility to ankylosing spondylitis. Eur J Immunol 1995; 25:3199.</a></li><li><a class="nounderline abstract_t">Koh WH, Boey ML. Ankylosing spondylitis in Singapore: a study of 150 patients and a local update. Ann Acad Med Singapore 1998; 27:3.</a></li><li><a class="nounderline abstract_t">Navid F, Holt V, Colbert RA. The enigmatic role of HLA-B*27 in spondyloarthritis pathogenesis. Semin Immunopathol 2021; 43:235.</a></li><li><a class="nounderline abstract_t">Asquith M, Sternes PR, Costello ME, et al. HLA Alleles Associated With Risk of Ankylosing Spondylitis and Rheumatoid Arthritis Influence the Gut Microbiome. Arthritis Rheumatol 2019; 71:1642.</a></li><li><a class="nounderline abstract_t">Xu H, Yin J. HLA risk alleles and gut microbiome in ankylosing spondylitis and rheumatoid arthritis. Best Pract Res Clin Rheumatol 2019; 33:101499.</a></li><li><a class="nounderline abstract_t">Madden DR, Gorga JC, Strominger JL, Wiley DC. The structure of HLA-B27 reveals nonamer self-peptides bound in an extended conformation. Nature 1991; 353:321.</a></li><li><a class="nounderline abstract_t">Madden DR, Gorga JC, Strominger JL, Wiley DC. The three-dimensional structure of HLA-B27 at 2.1 A resolution suggests a general mechanism for tight peptide binding to MHC. Cell 1992; 70:1035.</a></li><li><a class="nounderline abstract_t">Yamaguchi A, Tsuchiya N, Mitsui H, et al. Association of HLA-B39 with HLA-B27-negative ankylosing spondylitis and pauciarticular juvenile rheumatoid arthritis in Japanese patients. Evidence for a role of the peptide-anchoring B pocket. Arthritis Rheum 1995; 38:1672.</a></li><li><a class="nounderline abstract_t">Bowness P. HLA-B27. Annu Rev Immunol 2015; 33:29.</a></li><li><a class="nounderline abstract_t">Ben Dror L, Barnea E, Beer I, et al. The HLA-B*2705 peptidome. Arthritis Rheum 2010; 62:420.</a></li><li><a class="nounderline abstract_t">López de Castro JA. The HLA-B27 peptidome: building on the cornerstone. Arthritis Rheum 2010; 62:316.</a></li><li><a class="nounderline abstract_t">Faham M, Carlton V, Moorhead M, et al. Discovery of T Cell Receptor β Motifs Specific to HLA-B27-Positive Ankylosing Spondylitis by Deep Repertoire Sequence Analysis. Arthritis Rheumatol 2017; 69:774.</a></li><li><a class="nounderline abstract_t">Yin J, Sternes PR, Wang M, et al. Shotgun metagenomics reveals an enrichment of potentially cross-reactive bacterial epitopes in ankylosing spondylitis patients, as well as the effects of TNFi therapy upon microbiome composition. Ann Rheum Dis 2020; 79:132.</a></li><li><a class="nounderline abstract_t">Garrido-Mesa J, Brown MA. T cell Repertoire Profiling and the Mechanism by which HLA-B27 Causes Ankylosing Spondylitis. Curr Rheumatol Rep 2022; 24:398.</a></li><li><a class="nounderline abstract_t">Yang X, Garner LI, Zvyagin IV, et al. Autoimmunity-associated T cell receptors recognize HLA-B*27-bound peptides. Nature 2022; 612:771.</a></li><li><a class="nounderline abstract_t">Allen RL, Bowness P, McMichael A. The role of HLA-B27 in spondyloarthritis. Immunogenetics 1999; 50:220.</a></li><li><a class="nounderline abstract_t">Allen RL, O'Callaghan CA, McMichael AJ, Bowness P. Cutting edge: HLA-B27 can form a novel beta 2-microglobulin-free heavy chain homodimer structure. J Immunol 1999; 162:5045.</a></li><li><a class="nounderline abstract_t">Shaw J, Hatano H, Kollnberger S. The biochemistry and immunology of non-canonical forms of HLA-B27. Mol Immunol 2014; 57:52.</a></li><li><a class="nounderline abstract_t">Ranganathan V, Gracey E, Brown MA, et al. Pathogenesis of ankylosing spondylitis - recent advances and future directions. Nat Rev Rheumatol 2017; 13:359.</a></li><li><a class="nounderline abstract_t">Colbert RA, DeLay ML, Layh-Schmitt G, Sowders DP. HLA-B27 misfolding and spondyloarthropathies. Prion 2009; 3:15.</a></li><li><a class="nounderline abstract_t">Mear JP, Schreiber KL, Münz C, et al. Misfolding of HLA-B27 as a result of its B pocket suggests a novel mechanism for its role in susceptibility to spondyloarthropathies. J Immunol 1999; 163:6665.</a></li><li><a class="nounderline abstract_t">Smith JA. The role of the unfolded protein response in axial spondyloarthritis. Clin Rheumatol 2016; 35:1425.</a></li><li><a class="nounderline abstract_t">Australo-Anglo-American Spondyloarthritis Consortium (TASC), Reveille JD, Sims AM, et al. Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nat Genet 2010; 42:123.</a></li><li><a class="nounderline abstract_t">Wellcome Trust Case Control Consortium, Australo-Anglo-American Spondylitis Consortium (TASC), Burton PR, et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet 2007; 39:1329.</a></li><li><a class="nounderline abstract_t">Evans DM, Spencer CC, Pointon JJ, et al. Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat Genet 2011; 43:761.</a></li><li><a class="nounderline abstract_t">Lin Z, Bei JX, Shen M, et al. A genome-wide association study in Han Chinese identifies new susceptibility loci for ankylosing spondylitis. Nat Genet 2011; 44:73.</a></li><li><a class="nounderline abstract_t">International Genetics of Ankylosing Spondylitis Consortium (IGAS), Cortes A, Hadler J, et al. Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat Genet 2013; 45:730.</a></li><li><a class="nounderline abstract_t">Brown MA, Kenna T, Wordsworth BP. Genetics of ankylosing spondylitis--insights into pathogenesis. Nat Rev Rheumatol 2016; 12:81.</a></li><li><a class="nounderline abstract_t">Brown MA, Edwards S, Hoyle E, et al. Polymorphisms of the CYP2D6 gene increase susceptibility to ankylosing spondylitis. Hum Mol Genet 2000; 9:1563.</a></li><li><a class="nounderline abstract_t">Tsui HW, Inman RD, Paterson AD, et al. ANKH variants associated with ankylosing spondylitis: gender differences. Arthritis Res Ther 2005; 7:R513.</a></li><li><a class="nounderline abstract_t">Zhu X, Wang Y, Sun L, et al. A novel gene variation of TNFalpha associated with ankylosing spondylitis: a reconfirmed study. Ann Rheum Dis 2007; 66:1419.</a></li><li><a class="nounderline abstract_t">Ellinghaus D, Jostins L, Spain SL, et al. Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. Nat Genet 2016; 48:510.</a></li><li><a class="nounderline abstract_t">Robinson PC, Brown MA. Genetics of ankylosing spondylitis. Mol Immunol 2014; 57:2.</a></li><li><a class="nounderline abstract_t">Kanaseki T, Blanchard N, Hammer GE, et al. ERAAP synergizes with MHC class I molecules to make the final cut in the antigenic peptide precursors in the endoplasmic reticulum. Immunity 2006; 25:795.</a></li><li><a class="nounderline abstract_t">Nakamura A, Boroojeni SF, Haroon N. Aberrant antigen processing and presentation: Key pathogenic factors leading to immune activation in Ankylosing spondylitis. Semin Immunopathol 2021; 43:245.</a></li><li><a class="nounderline abstract_t">Nam B, Jo S, Bang SY, et al. Clinical and genetic factors associated with radiographic damage in patients with ankylosing spondylitis. Ann Rheum Dis 2023; 82:527.</a></li><li><a class="nounderline abstract_t">Berlinberg A, Kuhn KA. Molecular Biology Approaches to Understanding Spondyloarthritis. Rheum Dis Clin North Am 2020; 46:203.</a></li><li><a class="nounderline abstract_t">Maksymowych WP, Chiowchanwisawakit P, Clare T, et al. Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: evidence of a relationship between inflammation and new bone formation. Arthritis Rheum 2009; 60:93.</a></li><li><a class="nounderline abstract_t">Poddubnyy D, Sieper J. Mechanism of New Bone Formation in Axial Spondyloarthritis. Curr Rheumatol Rep 2017; 19:55.</a></li><li><a class="nounderline abstract_t">Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet 2017; 390:73.</a></li><li><a class="nounderline abstract_t">Gravallese EM, Schett G. Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis. Nat Rev Rheumatol 2018; 14:631.</a></li><li><a class="nounderline abstract_t">Liu CH, Raj S, Chen CH, et al. HLA-B27-mediated activation of TNAP phosphatase promotes pathogenic syndesmophyte formation in ankylosing spondylitis. J Clin Invest 2019; 129:5357.</a></li><li><a class="nounderline abstract_t">Ranganathan V, Ciccia F, Zeng F, et al. Macrophage Migration Inhibitory Factor Induces Inflammation and Predicts Spinal Progression in Ankylosing Spondylitis. Arthritis Rheumatol 2017; 69:1796.</a></li><li><a class="nounderline abstract_t">Nakamura A, Talukdar A, Nakamura S, et al. Bone formation in axial spondyloarthritis: Is disease modification possible? Best Pract Res Clin Rheumatol 2019; 33:101491.</a></li></ol></div><div id="topicVersionRevision">Topic 7792 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23288559" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Are spondylarthritides related but distinct conditions or a single disease with a heterogeneous phenotype?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26708278" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Migration and Tissue Tropism of Innate Lymphoid Cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23910729" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The critical role of interleukin-23 in spondyloarthropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17665431" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The mystery of HLA-B27: if it isn't one thing, it's another.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9336417" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11053066" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Recurrence risk modelling of the genetic susceptibility to ankylosing spondylitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4123836" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Ankylosing spondylitis and HL-A 27.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30445480" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Therapies in ankylosing spondylitis-from clinical trials to clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21508345" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Prostaglandins and inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26656660" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : TNF biology, pathogenic mechanisms and emerging therapeutic strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33268443" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Immune response profiling of patients with spondyloarthritis reveals signalling networks mediating TNF-blocker function in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28270233" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Mechanistic rationales for targeting interleukin-17A in spondyloarthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31278139" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28518156" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Interleukin 17 is a chief orchestrator of immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29040753" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : What is the best treatment target in axial spondyloarthritis: tumour necrosis factorα, interleukin 17, or both?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33485992" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Exploring IL-17 in spondyloarthritis for development of novel treatments and biomarkers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26564856" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A gut-vascular barrier controls the systemic dissemination of bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27789760" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The evidence for microbiome manipulation in inflammatory arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24841232" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Relevance of the gut/joint axis for the management of spondyloarthritis in daily clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21744132" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Mucosal inflammation in spondylarthritides: past, present, and future.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21152001" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Association of variants at 1q32 and STAT3 with ankylosing spondylitis suggests genetic overlap with Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26215401" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Review: animal models as a tool to dissect pivotal pathways driving spondyloarthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22861806" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Defining the human microbiome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25651997" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Dysbiosis of the gut microbiota in disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25964341" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Identifying personal microbiomes using metagenomic codes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27390077" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Brief Report: Dialister as a Microbial Marker of Disease Activity in Spondyloarthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25417597" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Intestinal dysbiosis in ankylosing spondylitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28606969" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Faecal microbiota study reveals specific dysbiosis in spondyloarthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32340697" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Intestinal Microbiota, HLA-B27, and Spondyloarthritis: Dangerous Liaisons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32173258" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The microbiome in spondyloarthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28069576" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Dysbiosis and zonulin upregulation alter gut epithelial and vascular barriers in patients with ankylosing spondylitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28521565" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27915228" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Cytokines IL-17 and IL-22 in the host response to infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30225992" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29945918" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34113018" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Ankylosing spondylitis: an autoimmune or autoinflammatory disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33569634" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Novel immune cell phenotypes in spondyloarthritis pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23469373" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Shades of grey--the blurring view of innate and adaptive immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30008717" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : It Takes "Guts" to Cause Joint Inflammation: Role of Innate-Like T Cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23084357" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Innate lymphoid cell interactions with microbiota: implications for intestinal health and disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25902790" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28511289" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Brief Report: Group 3 Innate Lymphoid Cells in Human Enthesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26599385" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Subclinical gut inflammation in ankylosing spondylitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24334217" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : α4β7 integrin: beyond T cell trafficking.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29158573" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Enthesitis: from pathophysiology to treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30397205" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Mechanical strain determines the site-specific localization of inflammation and tissue damage in arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32080619" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Tendon and ligament mechanical loading in the pathogenesis of inflammatory arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33544244" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Cytokine "fine tuning" of enthesis tissue homeostasis as a pointer to spondyloarthritis pathogenesis with a focus on relevant TNF and IL-17 targeted therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31772947" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The Proportion of Regulatory T Cells in Patients with Ankylosing Spondylitis: A Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37532285" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Proteomic and genomic profiling of plasma exosomes from patients with ankylosing spondylitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4688372" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : High association of an HL-A antigen, W27, with ankylosing spondylitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22487796" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Genetics of spondyloarthritis--beyond the MHC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23673483" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Structural and dynamic features of HLA-B27 subtypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19772829" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Recent studies on the genetic basis of ankylosing spondylitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19772829" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Recent studies on the genetic basis of ankylosing spondylitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23916069" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : HLA-B27 and antigen presentation: at the crossroads between immune defense and autoimmunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14734520" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Presentation of a self-peptide in two distinct conformations by a disease-associated HLA-B27 subtype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7489765" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Relevance of residue 116 of HLA-B27 in determining susceptibility to ankylosing spondylitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9588266" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Ankylosing spondylitis in Singapore: a study of 150 patients and a local update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33481054" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The enigmatic role of HLA-B*27 in spondyloarthritis pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31038287" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : HLA Alleles Associated With Risk of Ankylosing Spondylitis and Rheumatoid Arthritis Influence the Gut Microbiome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32279929" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : HLA risk alleles and gut microbiome in ankylosing spondylitis and rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1922337" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The structure of HLA-B27 reveals nonamer self-peptides bound in an extended conformation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1525820" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : The three-dimensional structure of HLA-B27 at 2.1 A resolution suggests a general mechanism for tight peptide binding to MHC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7488289" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Association of HLA-B39 with HLA-B27-negative ankylosing spondylitis and pauciarticular juvenile rheumatoid arthritis in Japanese patients. Evidence for a role of the peptide-anchoring B pocket.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25861975" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : HLA-B27.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20112406" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The HLA-B*2705 peptidome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20112362" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The HLA-B27 peptidome: building on the cornerstone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28002888" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Discovery of T Cell ReceptorβMotifs Specific to HLA-B27-Positive Ankylosing Spondylitis by Deep Repertoire Sequence Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31662318" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Shotgun metagenomics reveals an enrichment of potentially cross-reactive bacterial epitopes in ankylosing spondylitis patients, as well as the effects of TNFi therapy upon microbiome composition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36197645" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : T cell Repertoire Profiling and the Mechanism by which HLA-B27 Causes Ankylosing Spondylitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36477533" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Autoimmunity-associated T cell receptors recognize HLA-B*27-bound peptides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10602882" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : The role of HLA-B27 in spondyloarthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10227970" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Cutting edge: HLA-B27 can form a novel beta 2-microglobulin-free heavy chain homodimer structure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23910730" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : The biochemistry and immunology of non-canonical forms of HLA-B27.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28446810" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Pathogenesis of ankylosing spondylitis - recent advances and future directions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19363299" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : HLA-B27 misfolding and spondyloarthropathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10586062" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Misfolding of HLA-B27 as a result of its B pocket suggests a novel mechanism for its role in susceptibility to spondyloarthropathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26567900" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : The role of the unfolded protein response in axial spondyloarthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20062062" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17952073" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21743469" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22138694" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : A genome-wide association study in Han Chinese identifies new susceptibility loci for ankylosing spondylitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23749187" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26439405" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Genetics of ankylosing spondylitis--insights into pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10861282" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Polymorphisms of the CYP2D6 gene increase susceptibility to ankylosing spondylitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15899038" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : ANKH variants associated with ankylosing spondylitis: gender differences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17472990" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : A novel gene variation of TNFalpha associated with ankylosing spondylitis: a reconfirmed study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26974007" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23916070" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Genetics of ankylosing spondylitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17088086" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : ERAAP synergizes with MHC class I molecules to make the final cut in the antigenic peptide precursors in the endoplasmic reticulum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33532928" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Aberrant antigen processing and presentation: Key pathogenic factors leading to immune activation in Ankylosing spondylitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36543524" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Clinical and genetic factors associated with radiographic damage in patients with ankylosing spondylitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32340696" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Molecular Biology Approaches to Understanding Spondyloarthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19116919" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: evidence of a relationship between inflammation and new bone formation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28752489" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Mechanism of New Bone Formation in Axial Spondyloarthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28110981" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Axial spondyloarthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30266977" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31682238" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : HLA-B27-mediated activation of TNAP phosphatase promotes pathogenic syndesmophyte formation in ankylosing spondylitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28597514" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Macrophage Migration Inhibitory Factor Induces Inflammation and Predicts Spinal Progression in Ankylosing Spondylitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32305314" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Bone formation in axial spondyloarthritis: Is disease modification possible?</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
